News

Nuvaira’s targeted lung denervation (TLD) therapy lowers the risk of hospitalization due to exacerbations in people with chronic obstructive pulmonary disease (COPD), Phase 2 trial data show, according to a company press release. A new clinical study, called AIRFLOW-3 (NCT03639051), is currently recruiting COPD patients at multiple…

Use of electronic cigarettes (e-cigarettes) is associated with an increased risk of respiratory diseases, including chronic obstructive pulmonary disease (COPD), among young adults, irrespective of other tobacco product use, a large U.S.-based study shows. Compared to healthy people, those currently using e-cigarettes, commonly called vaping, had a 43% increased…

Enrollment in a clinical trial evaluating the mechanism of action of RejuvenAir Metered Cryospray, CSA Medical’s investigational approach for the treatment of chronic bronchitis, has already passed the halfway point, the company announced. However, adults ages 40-79 with chronic bronchitis are still being recruited at the University…

Inhibiting a protein called lymphotoxin beta receptor (LTβR) could be an effective therapeutic strategy for chronic obstructive pulmonary disease (COPD), new research suggests. The findings were published in Nature, in the study “Inhibition of LTβR signalling activates WNT-induced regeneration in lung.” COPD is characterized by the…

Health Care Service Corporation (HCSC) has issued a positive coverage policy for Pulmonx’s Zephyr Endobronchial Valve for treating severe emphysema, a form of chronic obstructive pulmonary disease (COPD). HCSC is the largest customer-owned health insurer in the U.S., and the fifth largest insurer…

The U.S. Food and Drug Administration has granted clearance to PulmoScan, a device developed by Cognita Labs that will facilitate at-home testing of lung function. The device could be useful in providing care to people with respiratory conditions such as asthma and chronic obstructive pulmonary disease…